≡ Content Category ≡ Main Menu

Research

Photo courtesy NASA

Editors' Note: The following blog post first appeared on Forbes.com. In his seventh and last State of the Union address on January 12th, President Barack Obama announced a “moonshot” with the goal of making “America the country that cures cancer once and for all.” The “moonshot” program is to be led by Vice President Joe Read More

Still1_Steve_Porcelli_No_Text

Tuberculosis (TB) is an ancient disease that has afflicted humans since the dawn of civilization and remains very much with us even now. In fact, more people will probably die from TB in 2016 than from any other single infectious disease, with HIV a close second. This grim fact is well documented by annual reports Read More

Dr. Steven Walkley, Albert Einstein College of Medicine

Editors’ Note: February 29 marks the ninth annual Rare Disease Day, a worldwide event devoted to raising awareness of more than 6,500 rare diseases, of which less than 5 percent have any available treatment. We spoke with Dr. Steven Walkley, director of the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center and professor in Read More

Still image from the film, Spying on Breast Cancer Metastasis

One of my favorite shows to watch as a kid was Bill Nye the Science Guy. I fondly recall being glued to the television as Bill enthusiastically explained the mysterious wonders of the universe with all of his props, gizmos and gadgets. Unlike science teachers at school, whose seemingly endless lectures bored me, Bill Nye’s Read More

brain-test1

What excites a scientist’s brain? Is it the next big breakthrough experiment that will save humanity? Is it the approval of the R01 grant that will guarantee another few years of life in the laboratory? No. According to a recent study from the University of Lübeck, in Germany, what really tickles a scientist’s brain is Read More

syringe being used to draw liquid from a vial

In June, a U.S. Food and Drug Administration (FDA) advisory committee overwhelmingly recommended approval of two new drugs for cholesterol lowering, alirocumab (brand name Praluent, manufactured by Sanofi-Aventis) and evolocumab (Repatha, manufactured by Amgen). A final FDA decision is still pending, but is expected to take into account the advisory committee’s recommendation and should come Read More